Get the Stockscreener App
16.23
1.05%
0.205
Denali Therapeutics Inc stock is traded at $16.23, with a volume of 198.76K.
It is up +1.05% in the last 24 hours and down -18.90% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$16.02
Open:
$16.13
24h Volume:
198.76K
Relative Volume:
0.13
Market Cap:
$2.53B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-5.693
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-1.35%
1M Performance:
-18.90%
6M Performance:
+10.20%
1Y Performance:
-18.32%
1-Day Range:
$16.00
$16.36
1-Week Range:
$15.34
$16.68
52-Week Range:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
16.23 | 2.50B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.70 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
393.09 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.04 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.03 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics outlines key milestones for 2026 By Investing.com - Investing.com Canada
Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision - TipRanks
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome - The Manila Times
Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets
Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan
What insider trading reveals about Denali Therapeutics Inc. stock - Улправда
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
DNLI Reports Upbeat Longer-Term Data From Hunter Syndrome Study - MSN
Smart Money: Is Denali Therapeutics Inc stock recession proofM&A Rumor & Daily Technical Stock Forecast Reports - moha.gov.vn
Hunter Syndrome Treatment Market is expected to reach US$ - openPR.com
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial - Investing.com Nigeria
Understanding Momentum Shifts in (DNLI) - Stock Traders Daily
Denali Therapeutics stock holds Buy rating at Jefferies on FDA approval confidence - Investing.com Nigeria
Denali’s Hunter syndrome therapy shows promise in Phase 1/2 trial By Investing.com - Investing.com South Africa
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - The Manila Times
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II) - GlobeNewswire Inc.
Denali Therapeutics Earnings Notes - Trefis
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
3 Biotech Stocks With Major 2026 Catalysts - Yahoo Finance
Denali Therapeutics clears technical benchmark, hitting 80-plus RS rating - MSN
What drives Denali Therapeutics Inc 4DN stock priceIPO Market Watch & Free Expert Stock Watchlists - earlytimes.in
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
BTIG reiterates Denali Therapeutics (DNLI) buy recommendation - MSN
Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance
How Investors May Respond To Denali Therapeutics (DNLI) $200 Million Equity Raise And FDA Voucher Talks - Yahoo Finance
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50? - Insider Monkey
What risks investors should watch in Denali Therapeutics Inc. stockWeekly Risk Report & Free Community Supported Trade Ideas - Улправда
15 Most Promising Mid-Cap Healthcare Stocks Under $50 - Insider Monkey
Is Denali Therapeutics Inc. stock a good choice for value investorsWeekly Volume Report & Expert Curated Trade Setup Alerts - Улправда
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Analyst Downgrade: Will Denali Therapeutics Inc. stock reach all time highs in 2025Weekly Market Report & Daily Stock Trend Watchlist - Улправда
Is Denali Therapeutics Inc. stock positioned for digital transformation2025 Market Trends & Daily Volume Surge Signals - Улправда
Can Denali Therapeutics Inc. (4DN) stock sustain institutional flowsQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - Улправда
What dividend safety score for Denali Therapeutics Inc. stockJuly 2025 Big Picture & High Accuracy Investment Signals - DonanımHaber
Is Denali Therapeutics Inc. (4DN) stock a good hedge against inflationEarnings Growth Summary & Low Risk High Win Rate Picks - DonanımHaber
Is Denali Therapeutics Inc. stock recession proof2025 Support & Resistance & Detailed Earnings Play Strategies - DonanımHaber
What Wall Street predicts for Denali Therapeutics Inc. stock priceEarnings Miss & AI Enhanced Trading Alerts - DonanımHaber
What catalysts could drive Denali Therapeutics Inc. stock higherFed Meeting & Technical Buy Zone Confirmations - Улправда
Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy? - simplywall.st
Revenue per share of Denali Therapeutics Inc. – DUS:4DN - TradingView — Track All Markets
Beyond Weight Loss: The "Cellular Reset" That Could Create the Next Biotech Supercycle - The Globe and Mail
Denali Therapeutics (DNLI) funds add $0.01 prefunded warrants in public offering - Stock Titan
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - MarketBeat
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating - marketscreener.com
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schuth Alexander O. | COFO and Secretary |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
242,346 |
| Ho Carole | Chief Medical Officer |
Aug 12 '25 |
Sale |
13.58 |
2,937 |
39,884 |
217,391 |
| Ho Carole | Chief Medical Officer |
Aug 13 '25 |
Sale |
14.64 |
806 |
11,800 |
216,585 |
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):